Offsetting Liabilities [Line Items] Offsetting Liabilities [Line Items] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Award Timing Predetermined Award Timing Predetermined [Flag] Tax deficiencies/(excess tax benefits) from share-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Total lease liabilities Operating And Finance Lease, Liability Operating And Finance Lease, Liability Tabular List, Table Tabular List [Table Text Block] Adoption of New Accounting Standards and Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Finance Leases Finance Lease, Liability [Abstract] GW Incentive Plans, Post Acquisition Grants GW Incentive Plans, Post Acquisition Grants [Member] GW Incentive Plans, Post Acquisition Grants Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Domestic tax effects Domestic Tax Effects Percent [Abstract] Domestic Tax Effects Percent Research and orphan drug tax credits Research and other tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Xyrem Xyrem [Member] Xyrem [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Total long-lived assets Property, Plant And Equipment, Net, And Operating Lease Right-Of-Use Assets Property, Plant And Equipment, Net, And Operating Lease Right-Of-Use Assets Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenues Revenue from Contract with Customer [Text Block] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract] Clinical trial accruals Accrued Clinical Trial Liability, Current Accrued Clinical Trial Liability, Current Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of ordinary shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Total current tax expense Current income tax expense (benefit) Current Income Tax Expense (Benefit) Inventory-related accruals Accrued Inventory Related Liabilities, Current Accrued Inventory Related Liabilities, Current Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentration risk, percentage Percentage of total revenues (as a percent) Concentration Risk, Percentage Basis of Presentation Consolidation, Policy [Policy Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Foreign derived intangible income benefit Effective Income Tax Rate Reconciliation, FDII, Amount Share Options Share-Based Payment Arrangement, Option [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Finance Lease Cost Finance Lease Cost1 [Abstract] Finance Lease Cost1 Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Significant Risks and Uncertainties Significant Risks And Uncertainties [Policy Text Block] Describes risks and uncertainties related to the pharmaceutical industry. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Cash and Available-for-Sale Securities Cash, Cash Equivalent, and Short-Term Investment [Text Block] Cash dividends declared or paid Dividends, Common Stock, Cash Tax expense effect on cash flow hedging activities reclassified Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Insider Trading Policies and Procedures [Line Items] Schedule of Property, Plant and Equipment Estimated Useful Life Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Ordinary shares, authorized (in shares) Common Stock, Shares Authorized Concentrations of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Non-voting euro deferred shares, authorized (in shares) Nonvoting Euro Preferred Shares, Shares Authorized Nonvoting Euro Preferred Shares, Shares Authorized Non-deductible contingent consideration payments Effective Income Tax Rate Reconciliation, Non-Deductible Contingent Consideration Payments, Amount Effective Income Tax Rate Reconciliation, Non-Deductible Contingent Consideration Payments, Amount LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] U.S. State State and Local Jurisdiction [Member] Cover [Abstract] Cover [Abstract] Lumryz Product For Non-Narcolepsy Indications, Unpermitted Net Sales Lumryz Product For Non-Narcolepsy Indications, Unpermitted Net Sales [Member] Lumryz Product For Non-Narcolepsy Indications, Unpermitted Net Sales Maximum Maximum [Member] Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Unrecognized tax benefits, accrued interest Unrecognized Tax Benefits, Interest on Income Taxes Accrued Total Finite-Lived Intangible Assets, Net Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Epidiolex/Epidyolex Epidiolex/Epidyolex [Member] Epidiolex/Epidyolex Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of RSU and PRSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] 2021 Notes Exchangeable Senior Notes Due 2021 [Member] Exchangeable Senior Notes Due 2021 [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Shell Company Entity Shell Company 2011 Equity Incentive Plan Two Thousand Eleven Equity Incentive Plan [Member] Two Thousand Eleven Equity Incentive Plan [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Inventory, step-up value Inventory, Step-Up Value Inventory, Step-Up Value 2026 Notes Exchangeable Senior Notes Due 2026 [Member] Exchangeable Senior Notes Due 2026 [Member] Schedule of Income Taxes Paid, Net of Refunds Received Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Unrealized gain on cash flow hedging activities, net of income tax expense of $65, $1,760 and $1,215, respectively Gain recognized in accumulated other comprehensive loss, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Offsetting Liabilities [Table] Offsetting Liabilities [Table] Ireland Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of Share-based Compensation Expense Related to Share Options, RSUs, PSRUs and Grants Under ESPP Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Operating lease liabilities Operating Lease, Liability, Current Interest on lease liabilities Finance Lease, Interest Expense Computer software Software and Software Development Costs [Member] Document Fiscal Period Focus Document Fiscal Period Focus Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] Furniture and fixtures Furniture and fixtures Furniture and Fixtures [Member] Award Type [Axis] Award Type [Axis] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Methods of Treatment when Administered with other Medications Methods Of Treatment When Administered With Other Medications [Member] Methods Of Treatment When Administered With Other Medications Hedging Relationship [Domain] Hedging Relationship [Domain] Share-Based Compensation and Performance-Based Restricted Stock Unit Awards Share-Based Payment Arrangement [Policy Text Block] Trading Symbol Trading Symbol Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Business Acquisitions Business Combination [Policy Text Block] Non-voting euro deferred shares, issued (in shares) Nonvoting Euro Deferred Shares, Shares Issued Nonvoting Euro Deferred Shares, Shares Issued Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Shares issued (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town Finance leases Finance Lease, Weighted Average Discount Rate, Percent Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Decreases related to settlements with taxing authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Cost of product sales (excluding amortization of acquired developed technologies) Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment Total costs related to goods produced and sold during the reporting period excluding amortization of acquired developed technologies and intangible asset impairment presented separately. Emerging Growth Company Entity Emerging Growth Company 2028 Long-Term Debt, Maturity, Year Three Debt covenant, maturity date extension option, number of days after Amended Revolving Facility Maturity Date Debt Instrument, Covenant, Maturity Date Extension Option, Number Of Days After Amended Revolving Facility Maturity Date Debt Instrument, Covenant, Maturity Date Extension Option, Number Of Days After Amended Revolving Facility Maturity Date Acquisition of intangible assets Payments to Acquire Intangible Assets Finance leases Finance Lease, Weighted Average Remaining Lease Term Net income (loss) per ordinary share: Net Income (Loss) Per Ordinary Share [Abstract] Net Income (Loss) Per Ordinary Share Cash Collateral Received (Pledged) Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Repayments under revolving credit facility Repayments of Lines of Credit Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Debt issuance cost Debt Issuance Costs, Net Gain (loss) recognized in foreign exchange gain (loss) Derivative, Gain (Loss) on Derivative, Net Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Ordinary shares, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Debt Interest Rate Period Two Debt Interest Rate Period Two [Member] Debt Interest Rate Period Two Allowance for doubtful accounts SEC Schedule, 12-09, Allowance, Credit Loss [Member] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] U.S. Federal Internal Revenue Service (IRS) [Member] Royalty rate for sales to be received Royalty Rate For Sales To Be Received Royalty Rate For Sales To Be Received Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Issuance of ordinary shares in conjunction with exercise of share options Stock Issued During Period, Value, Stock Options Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Schedule of Total Long-lived Assets by Location Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Estimated Future Amortization Costs Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Number of RSUs and PRSUs [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Effective interest rate (as a percentage) Debt Instrument, Interest Rate, Effective Percentage Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Income tax benefit Total income tax expense (benefit) Income tax (benefit) expense Income Tax Expense (Benefit) Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate 2011 Plan 2011 Plan [Member] 2011 Plan Income tax expense effect on cash flow hedging activities Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Derivatives designated as hedging instruments Designated as Hedging Instrument [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Relationship [Axis] Hedging Relationship [Axis] Initial Grant Initial Grant [Member] Initial Grant [Member] Prime Rate Prime Rate [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] De-recognition of operating lease liability on lease assignment / termination De-Recognition Of Operating Lease Liability On Lease Assignment / Termination De-Recognition Of Operating Lease Liability On Lease Assignment / Termination SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Ireland Income Tax Paid, Federal, after Refund Received All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Redemption price, percentage (as a percentage) Debt Instrument, Redemption Price, Percentage Accrued liabilities Accrued liabilities Accrued Liabilities, Current Contingencies Commitments and Contingencies, Policy [Policy Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Number of RSUs and PRSUs, outstanding, beginning balance (in shares) Number of RSUs and PRSUs, outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Debt term (in years) Debt Instrument, Term Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Estimated useful life of property and equipment Property, Plant and Equipment, Useful Life Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Subsequent Event Subsequent Event [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Bruce C. Cozaad [Member] Bruce C. Cozaad Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Redx Pharma Redx Pharma [Member] Redx Pharma PEO Total Compensation Amount PEO Total Compensation Amount Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Depreciation Depreciation Non-deductible acquired in-process research and development expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Money market funds Money Market Funds [Member] Debt Instrument, Redemption, Period Three Debt Instrument, Redemption, Period Three [Member] Cash Asset Acquisition, Cash and Equivalents Asset Acquisition, Recognized Asset Acquired, Cash Performance-Based Restricted Stock Units (PRSUs) Performance-Based Restricted Stock Units (RSUs) [Member] Performance-Based Restricted Stock Units (RSUs) 2029 Finance Lease, Liability, to be Paid, Year Four Gross Amounts of Recognized Assets/ Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Sublease income Sublease Income Convertible Debt Convertible Debt [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt covenant, revolving credit facility, outstanding amount threshold Debt Covenant, Outstanding Amount Threshold Debt Covenant, Outstanding Amount Threshold Number of Reportable Segments Number of Reportable Segments Options expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Advertising Expenses Advertising Cost [Policy Text Block] Computer software and equipment Computer Software And Equipment [Member] Computer Software And Equipment [Member] Entity Address, Country Entity Address, Country Financing cash outflows from finance leases Finance Lease, Principal Payments Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Asset Acquisition, Consideration Transferred, Equity Interest, Type [Domain] Asset Acquisition, Consideration Transferred, Equity Interest, Type [Domain] Asset Acquisition, Consideration Transferred, Equity Interest, Type [Domain] Foreign tax effects Foreign Tax Effects [Abstract] Foreign Tax Effects Total current liabilities Liabilities, Current Other All other Other Countries [Member] Other Countries [Member] Individual: Individual [Axis] Expenses related to defined contribution plans Defined Contribution Plan, Cost Property, plant and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Rebates and other sales deductions Accrued Rebates And Other Sales Deductions, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates and other sales deductions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Document Annual Report Document Annual Report Research and development Research and Development Expense [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other Deferred Other Tax Expense (Benefit) Capitalized research and development Deferred Tax Asset, In-Process Research and Development Entity Interactive Data Current Entity Interactive Data Current Zepzelca Zepzelca [Member] Zepzelca 2021 Credit Agreement, Revolving Credit Facility Two Thousand Twenty One Credit Agreement, Revolving Credit Facility [Member] Two Thousand Twenty One Credit Agreement, Revolving Credit Facility Accrued milestones Accrued Milestones, Current Accrued Milestones, Current Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Number of patents, paragraph IV certification notice filed Number Of Patents, Paragraph IV Certification Notice Filed Number Of Patents, Paragraph IV Certification Notice Filed Revenue Recognition and Cost of Product Sales Revenue from Contract with Customer [Policy Text Block] Non-deductible compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Schedule of Authorized but Unissued Ordinary Shares Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Ownership [Domain] Ownership [Domain] 2027 Finance Lease, Liability, to be Paid, Year Two Schedule of Lease Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Balance at beginning of period Balance at end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Other non-current assets Other Assets, Noncurrent Accrued interest Interest Payable, Current Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Debt conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount ESSDS Express Scripts [Member] Express Scripts 1 [Member] Total deferred, change in tax rates Deferred Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Deferred Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Senior Secured Debt Senior Secured Debt [Member] Senior Secured Debt Schedule of the Fair Value of Outstanding Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Work in process Inventory, Work in Process, Net of Reserves Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Unrecognized compensation cost related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Income tax at the statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Inventory, Current [Table] Inventory, Current [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] De-recognition of operating lease asset on lease assignment / termination De-Recognition Of Operating Lease Asset On Lease Assignment / Termination De-Recognition Of Operating Lease Asset On Lease Assignment / Termination Long-term debt, less current portion Total long-term debt Long-Term Debt, Excluding Current Maturities 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Debt covenant, term loan amount outstanding threshold Debt Instrument, Covenant, Term Loan Amount Outstanding Threshold Debt Instrument, Covenant, Term Loan Amount Outstanding Threshold Time deposits Bank Time Deposits [Member] Share price (in dollars per share) Asset Acquisition, Share Price Asset Acquisition, Share Price Upfront and milestone payment values Gross Carrying Amount Finite-Lived Intangible Assets, Gross July 2024 Share Repurchase Program July 2024 Share Repurchase Program [Member] July 2024 Share Repurchase Program Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accumulated Other Comprehensive Loss Total Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Total deferred, exclusive of other components Deferred Income Tax Expense (Benefit), Before Effect Of Change In Tax Rates Deferred Income Tax Expense (Benefit), Before Effect Of Change In Tax Rates Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Shares withheld for tax purposes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Ownership [Axis] Ownership [Axis] Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Stockholders' Equity Note [Line Items] Stockholders Equity Note [Line Items] Stockholders Equity Note [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value NOL carryforwards Operating Loss Carryforwards Credit Agreement June 2015 Credit Agreement June 2015 [Member] Credit Agreement June 2015 [Member] Worldwide changes in unrecognized tax benefits Change in unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Schedule of Carrying Amount of Indebtedness Schedule of Long-Term Debt Instruments [Table Text Block] Dilutive effect of employee equity incentive and purchase plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Number of RSUs and PRSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Acquisition of investments Payments to Acquire Investments Total operating expenses Costs and Expenses Unrecognized compensation cost related to grants under the PRSUs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Number of RSUs and PRSUs forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Summary Of Deferred Revenue [Line Items] Summary Of Deferred Revenue [Line Items] [Line Items] for Summary Of Deferred Revenue [Table] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Non-deductible contingent consideration payments Effective Income Tax Rate Reconciliation, Non-Deductible Contingent Consideration Payments, Percent Effective Income Tax Rate Reconciliation, Non-Deductible Contingent Consideration Payments, Percent Counterparty Name [Domain] Counterparty Name [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted-average remaining contractual term, outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Non-voting Euro Deferred Euro Deferred Shares [Member] Euro Deferred Shares [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Investments Investments Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Non-PEO NEO Non-PEO NEO [Member] Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Auditor Information [Abstract] Auditor Information Issuance of ordinary shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accumulated Other Comprehensive Income Loss [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Repayment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Award Type [Domain] Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Advertising expenses Advertising Expense Other non-cash transactions Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Effects of cross-border tax laws Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Deferred, exclusive of other components below Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Aggregate Intrinsic Value Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value [Abstract] Offsetting Assets [Table] Offsetting Assets [Table] Provision for losses on accounts receivable and inventory Provision For Losses On Accounts Receivable And Inventory Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction off the carrying amount of inventory, generally attributable to obsolescence or market conditions. Acquisition accounting inventory fair value step-up adjustment Inventory Step-Up Value Adjustment Inventory Step-Up Value Adjustment Sativex Sativex [Member] Sativex Additions charged to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Statutory tax rate difference Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Deferred Financing Costs Financing Costs [Policy Text Block] Financing Costs [Policy Text Block] Payment terms, range (in days) Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Revenues: Revenues [Abstract] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] 2026 Long-Term Debt, Maturity, Year One Financial Instruments [Domain] Financial Instruments [Domain] Total deferred tax liabilities Deferred Tax Liabilities, Gross Schedule of Impact on Accumulated Other Comprehensive Loss and Earnings (Loss) from Derivative Instruments that Qualified as Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] 2030 Long-Term Debt, Maturity, Year Five Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Gain on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax expense of $411, $1,593 and $1,137, respectively Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Non-deductible financing costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Financing Costs, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Financing Costs, Amount Inventories Total inventories Inventory, Net Acquired Developed Technologies Acquired developed technologies Developed Technology Rights [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name Xywav and Xyrem Xywav And Xyrem [Member] Xywav And Xyrem Debt Debt Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Operating cash outflows from operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net income (loss) for dilutive net income (loss) per ordinary share Net Income (Loss) Available to Common Stockholders, Diluted United kingdom and united states Current Foreign Tax Expense (Benefit) Goodwill [Roll Forward] Goodwill [Roll Forward] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted-average ordinary shares used in per share calculations - diluted (in shares) Weighted-average ordinary shares used in per share calculations - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average remaining contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Derivative [Table] Derivative [Table] Total net assets acquired Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Lumryz Product For Non-Narcolepsy Indications Lumryz Product For Non-Narcolepsy Indications [Member] Lumryz Product For Non-Narcolepsy Indications Smaller Reporting Company Entity Small Business Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Shares authorized for issuance under deferred compensation plan (in shares) Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance United kingdom and united states Deferred Foreign Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Deferred Foreign Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Product sales, net Product And Services, Product Sales Net Of Deductions [Member] Product And Services, Product Sales Net Of Deductions [Member] Document Transition Report Document Transition Report Total lease payments Finance Lease, Liability, to be Paid Underlying Securities Award Underlying Securities Amount Potential Milestone Payment Potential Milestone Payment [Member] Potential Milestone Payment Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Income Taxes Income Tax Disclosure [Text Block] United Kingdom UNITED KINGDOM General Composition and Method of Use General Composition And Method Of Use [Member] General Composition And Method Of Use Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Short-term lease cost Short-Term Lease, Cost Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Fair value of exchangeable senior notes Convertible Debt, Fair Value Disclosures Average price of shares repurchased (in dollars per share) Shares Acquired, Average Cost Per Share Accrued liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Document Type Document Type Net Income (Loss) per Ordinary Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Litigation expense Litigation Settlement, Loss Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Total Revenues Revenue from Contract with Customer Benchmark [Member] Variable lease cost Variable Lease, Cost Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Lupin Lawsuit Lupin Lawsuit [Member] Lupin Lawsuit Total consideration Asset Acquisition, Consideration Transferred Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Total amount authorized for repurchase of shares under share repurchase program Share Repurchase Program, Authorized, Amount Other assets and liabilities Asset Acquisition, Assets (Liabilities), Other Asset Acquisition, Assets (Liabilities), Other Accrued liabilities Accrued Liabilities [Member] Number of lawsuits filed Loss Contingency, New Claims Filed, Number Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate intrinsic value of share options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Payment of employee withholding taxes related to share-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Derivatives, maximum contract term Derivative, Term of Contract Share Repurchase Program [Domain] Share Repurchase Program [Domain] Minimum secured leverage ratio, for restricted payments to be allowed Debt Instrument, Covenant, Minimum Secured Leverage Ratio, For Restricted Payments To Be Allowed Debt Instrument, Covenant, Minimum Secured Leverage Ratio, For Restricted Payments To Be Allowed Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Weighted- Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Five Customers Five Customers [Member] Five Customers Non-taxable/non-deductible items Non-Taxable/Non-Deductible Items Percent [Abstract] Non-Taxable/Non-Deductible Items Percent Accrued liabilities Increase (Decrease) in Accrued Liabilities Diluted (in dollars per share) Earnings Per Share, Diluted Accounts receivable, net of allowances of $17,294 and $32,691 at December 31, 2025 and 2024, respectively Accounts Receivable, after Allowance for Credit Loss, Current 2024 Notes Exchangeable Senior Notes Due 2024 [Member] Exchangeable Senior Notes Due 2024 [Member] Capital Redemption Reserve Capital Redemption Reserve [Member] Capital Redemption Reserve [Member] Payment of debt modification costs Payments of Debt Restructuring Costs Derivative liability, statement of financial position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Total Oncology Total Oncology [Member] Total Oncology Auditor Location Auditor Location Non-cash interest expense Noncash Interest Expense Noncash Interest Expense Asset Acquisition [Table] Asset Acquisition [Table] Shares repurchased Stock repurchased and retired during period, value Stock Repurchased and Retired During Period, Value Ireland Domestic Tax Jurisdiction [Member] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Fair value of lines of credit Lines of Credit, Fair Value Disclosure Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Term Loan Term Loan Term Loan [Member] Term Loan [Member] Cash paid for income taxes, net of refunds Total cash paid for income taxes, net of refunds Income Taxes Paid, Net 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Long term debt outstanding Total Long-Term Debt, Gross Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Manufacturing contracts Manufacturing Contracts [Member] Manufacturing Contracts [Member] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Total lease payments Lessee, Operating Lease, Liability, to be Paid Upfront Payment Upfront Payments [Member] Upfront Payments [Member] Property, plant and equipment, net Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Expiration Date Trading Arrangement Expiration Date Other liabilities Increase (Decrease) in Other Operating Liabilities 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Five Weighted-average remaining contractual term, vested and exercisable to vest, exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Inventory, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Derivative [Line Items] Derivative [Line Items] Deduction on subsidiary equity carryforwards Deferred Tax Assets, Deductions On Subsidiary Equity Carryforwards Deferred Tax Assets, Deductions On Subsidiary Equity Carryforwards Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Net proceeds from issuance of 2030 Notes Proceeds from Convertible Debt Capital redemption reserve Capital Redemption Reserve Capital redemption reserve created under Irish company law to preserve permanent capital in the company. Income tax at the statutory tax rate Income tax expense at the statutory income tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Liability derivatives Derivative Liability, Gross Liability Including Not Subject to Master Netting Arrangement Financial Instrument [Axis] Financial Instrument [Axis] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] Foreign exchange forward contracts Foreign Exchange Forward [Member] Non-deductible compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] State and local income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Finance lease liabilities Finance Lease, Liability, Current Ordinary Shares Ordinary Shares [Member] Ordinary Shares [Member] Current Fiscal Year End Date Current Fiscal Year End Date Ireland IRELAND Stockholders' Equity Note [Table] Stockholders Equity Note [Table] Stockholders Equity Note [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Maximum secured leverage ratio, for restricted payments to be allowed Debt Instrument, Covenant, Maximum Secured Leverage Ratio, For Restricted Payments To Be Allowed Debt Instrument, Covenant, Maximum Secured Leverage Ratio, For Restricted Payments To Be Allowed Weighted-average discount rate Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate Weighted- Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Derivative Liability Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Derivative Liability Grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Cash Cash [Member] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Interest rate contracts Interest Rate Contract [Member] Accrued liabilities Asset Acquisition, Recognized Liability Assumed, Accrued Liabilities Asset Acquisition, Recognized Liability Assumed, Accrued Liabilities Italy ITALY Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Balance at the beginning of the year Balance at the end of the year Unrecognized Tax Benefits Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Ordinary shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] 2027 Long-Term Debt, Maturity, Year Two Leases Lessee, Operating Leases [Text Block] Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Deferred financing costs Debt Issuance Costs, Noncurrent, Net Denominator: Denominator [Abstract] Denominator [Abstract] Measure: Measure [Axis] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Net asset (liability) fair value Derivative, Fair Value, Net Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Remaining amount authorized for repurchase of shares Share Repurchase Program, Remaining Authorized, Amount Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Amortization of debt issuance costs Amortization of Debt Issuance Costs Entity Tax Identification Number Entity Tax Identification Number Asset Acquisition [Axis] Asset Acquisition [Axis] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Xyrem Antitrust Litigation Xyrem Antitrust Litigation [Member] Xyrem Antitrust Litigation Avadel Pharmaceuticals plc Lawsuit Avadel Pharmaceuticals plc Lawsuit [Member] Avadel Pharmaceuticals plc Lawsuit Ordinary shares, issued (in shares) Common Stock, Shares, Issued Derivative asset, statement of financial position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Operating leases Operating Lease, Weighted Average Remaining Lease Term 2029 Long-Term Debt, Maturity, Year Four Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Entity Public Float Entity Public Float 2030 Notes Convertible Debt Securities [Member] Schedule of Gross Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] Income taxes payable Increase (Decrease) in Income Taxes Payable Total Shareholder Return Amount Total Shareholder Return Amount Non-deductible financing costs Non-Taxable/Non-Deductible Items [Abstract] Non-Taxable/Non-Deductible Items Loss Contingencies [Line Items] Loss Contingencies [Line Items] Security Exchange Name Security Exchange Name Total foreign Income Tax Paid, Foreign, after Refund Received Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Maximum allowable dividend and restricted payments Debt Instrument, Covenant, Maximum Allowable Dividend And Restricted Payments Debt Instrument, Covenant, Maximum Allowable Dividend And Restricted Payments Operating expenses: Operating Expenses [Abstract] Prepaid expenses Prepaid Expense, Current Foreign tax effects Foreign Tax Effects Percent [Abstract] Foreign Tax Effects Percent Accrued development expenses Accrued Development Expenses, Current Accrued Development Expenses, Current Proceeds from sale of an asset Proceeds from Sale of Other Productive Assets Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalent Subsequent Event [Line Items] Subsequent Event [Line Items] Ordinary Shares Outstanding Common Stock Common Stock [Member] Number of RSUs released (in shares) Number of RSUs and PRSUs released (in shares) Number of RSUs and PRSUs released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period ASD ASD Specialty Healthcare LLC [Member] ASD Specialty Healthcare LLC Malta MALTA Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Consulting and professional services Accrued Professional Fees, Current Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Other current assets Other Current Assets [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating lease, liability, current, statement of financial position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Foreign Plan Foreign Plan [Member] Other non-current assets Other Noncurrent Assets [Member] Interest Rate Swap Interest Rate Swap [Member] Non-deductible facility expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Facility Expense, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Facility Expense, Amount Equity in loss of investees Income (Loss) from Equity Method Investments Leases [Abstract] Leases [Abstract] Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Valuation Allowance, Operating Loss Carryforwards SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member] Rylaze/Enrylaze Rylaze/Enrylaze [Member] Rylaze/Enrylaze Accounts payable Increase (Decrease) in Accounts Payable Interest expense, net Interest Income (Expense), Nonoperating Shares withheld for payment of employee's withholding tax liability Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in dollars per share) Earnings Per Share, Basic Liabilities: Liabilities, Fair Value Disclosure [Abstract] Authorized but unissued ordinary shares reserved (in shares) Common Stock, Capital Shares Reserved for Future Issuance Worldwide changes in unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Total deferred tax assets Deferred Tax Assets, Gross Recognized tax benefits related to share options exercised Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Conversion in excess of principal Debt Instrument, Convertible, If-converted Value in Excess of Principal Non-voting euro deferred shares, par value (in euros per share) Nonvoting Euro Deferred Shares, Par or Stated Value Per Share Nonvoting Euro Deferred Shares, Par or Stated Value Per Share Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Percentage of conversion price (as a percentage) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Schedule of Cash, Cash Equivalents and Investments Cash, Cash Equivalent, and Investment [Table Text Block] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] FDA stay of approval period (in months) FDA Stay Of Approval Period FDA Stay Of Approval Period 2028 Finance Lease, Liability, to be Paid, Year Three Contractual coupon rate interest expense Interest Expense, Debt, Contractual Coupon Rate Interest Expense, Debt, Contractual Coupon Rate Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Cash consideration Proceeds from Sale of Productive Assets Research and Development Research and Development Expense, Policy [Policy Text Block] Other comprehensive income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Total share-based compensation expense, pre-tax Share-Based Payment Arrangement, Expense Finance lease, liability, current, statement of financial position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Hedging Designation [Domain] Hedging Designation [Domain] Fair value of secured debt Notes Payable, Fair Value Disclosure Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current assets: Assets, Current [Abstract] Total liabilities and shareholders’ equity Liabilities and Equity Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares Subject to Outstanding Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Percentage of post-tax proceeds entitled Sale of Productive Asset, Percent Of Post-Tax Proceeds Entitled Sale of Productive Asset, Percent Of Post-Tax Proceeds Entitled Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Other Deferred Tax Assets, Other Number of consecutive days in trading period Debt Instrument, Convertible, Threshold Consecutive Trading Days Total share-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Derivative Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Accounting Policies [Abstract] Accounting Policies [Abstract] Allowance for chargebacks Allowance For Chargebacks [Member] Allowance For Chargebacks [Member] Schedule of Operating Lease Liability Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Asset Acquisition and License Agreements Asset Acquisition [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Repayments of long-term debt Repayments of Secured Debt Total fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Pay vs Performance Disclosure [Line Items] Tranche B 2 Dollar Term Loan Tranche B 2 Dollar Term Loan [Member] Tranche B 2 Dollar Term Loan Present value of lease liabilities Operating Lease, Liability Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Liabilities Liabilities [Abstract] Accrued collaboration expenses Accrued Collaboration Expenses, Current Accrued Collaboration Expenses, Current Totals Financial Liabilities Fair Value Disclosure Amortization of leased asset Finance Lease, Right-of-Use Asset, Amortization Debt instrument, redemption price, percentage of principal amount redeemed (as a percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Other non-current liabilities Other Liabilities, Noncurrent Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Current portion of long-term debt Less current portion Long-Term Debt, Current Maturities Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Options expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Name Measure Name Schedule of Components of [Income (Loss)] from Continuing Operations Before Income Tax Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Secured Debt Secured Debt [Member] Deferred tax liabilities, net Deferred tax liabilities Deferred Income Tax Liabilities, Net SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Total debt Long-Term Debt Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Jazz Investments I Limited Jazz Investments I Limited [Member] Jazz Investments I Limited [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Weighted-average grant-date fair value, RSUs and PRSUs released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Indirect effects of unrecognized tax benefits Deferred Tax Assets, Indirect Effects Of Unrecognized Tax Benefits Deferred Tax Assets, Indirect Effects Of Unrecognized Tax Benefits Geographical [Domain] Geographical [Domain] Debt Interest Rate Period Two, Term SOFR Floor Debt Interest Rate Period Two, Term SOFR Floor [Member] Debt Interest Rate Period Two, Term SOFR Floor Income Taxes Income Tax, Policy [Policy Text Block] Other Other Tax Expense (Benefit) Components of Net Deferred Tax Assets/(Liabilities) Components of Deferred Tax Assets and Liabilities [Abstract] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Research and orphan drug tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Remaining Weighted- Average Useful Life (In years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Concentration Risk Type [Axis] Concentration Risk Type [Axis] Inventories Inventory Disclosure [Text Block] Assets: Assets, Fair Value Disclosure [Abstract] 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense (Excluding Acquired in Process Cost) 2026 Finance Lease, Liability, to be Paid, Year One Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Operating lease assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lease Cost Lease, Cost [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] State and local income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] FDA recognition of orphan drug exclusivity, period (in years) FDA Recognition Of Orphan Drug Exclusivity, Period FDA Recognition Of Orphan Drug Exclusivity, Period Schedule of Details of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Plan Name [Axis] Plan Name [Axis] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] Proceeds from maturity of investments Proceeds from Sale, Maturity and Collection of Investments Interest income from available-for-sale securities Investment Income, Interest Intangible assets Deferred Tax Liabilities, Intangible Assets Income (loss) before income tax benefit and equity in loss of investees Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income Tax Paid, by Individual Jurisdiction [Line Items] Income Tax Paid, by Individual Jurisdiction [Line Items] United States United States - federal UNITED STATES Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Retained Earnings Retained Earnings [Member] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Derivative assets Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Derivative Asset Income taxes payable Taxes Payable, Current Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Xywav Xywav [Member] Xywav Product and Service [Domain] Product and Service [Domain] Effect of interest on assumed conversions of the 2026 Notes and the 2024 Notes, net of tax Interest on Convertible Debt, Net of Tax Available-for-sale securities: Debt Securities, Available-for-Sale [Abstract] Customer concentration risk Customer Concentration Risk [Member] Vested and exercisable to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Business Combination [Table] Business Combination [Table] Debt instrument, decrease in basis spread on variable rate Debt Instrument, Decrease In Basis Spread On Variable Rate Debt Instrument, Decrease In Basis Spread On Variable Rate Notional amount Derivative, Notional Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Sales return reserve Sales Return Reserve, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns reserve. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Income Tax Paid, by Individual Jurisdiction [Table] Income Tax Paid, by Individual Jurisdiction [Table] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Net deferred tax assets (liabilities) Deferred Tax Liabilities, Net Inventories Deferred Tax Liabilities, Inventory Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Number of purchase periods within each ESPP offering period Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Within Each Offering Period Number of purchase periods within a fixed offering period with respect to the plan. Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Net lease cost Lease, Cost Cost of product sales Cost of Sales [Member] Cash Flow Hedges Cash Flow Hedging [Member] Goodwill Goodwill, beginning of period Goodwill, end of period Goodwill Schedule of Lease Cost and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Pro Forma Pro Forma [Member] Impairment of property, plant and equipment Tangible Asset Impairment Charges Ireland Deferred Federal Income Tax Expense (Benefit) Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits Unrecognized Tax Benefits [Roll Forward] Asset Acquisition [Abstract] Auditor Name Auditor Name Tax deficiencies/(excess tax benefits) from share-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Concentration Risk [Table] Concentration Risk [Table] Organization and Description of Business Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] 2021 Credit Agreement, Euro Term Loan Two Thousand Twenty One Credit Agreement, Euro Term Loan [Member] Two Thousand Twenty One Credit Agreement, Euro Term Loan Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Inventory [Line Items] Inventory [Line Items] Additional expected tax expense if foreign earnings repatriated Additional Expected Tax Expense If Foreign Earnings Repatriated In The Future Additional Expected Tax Expense If Foreign Earnings Repatriated In The Future Annual Automatic Grant Annual Automatic Grant [Member] Annual Automatic Grant [Member] Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Net income (loss) per ordinary share: Earnings Per Share Reconciliation [Abstract] Leases Lessee, Finance Leases [Text Block] Other current assets Other Assets, Current Additional paid-in capital Additional Paid in Capital, Common Stock Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2025 and 2024 Nonvoting Euro Deferred Shares Shares issued to satisfy statutory minimum of Euro-denominated share capital required for a public limited company incorporated in Ireland. Entity [Domain] Entity [Domain] Selling and marketing accruals Accrued Marketing Costs, Current Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Deduction on subsidiary equity Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent Asset acquisition, net of cash acquired Payments to Acquire Assets, Investing Activities Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Document Fiscal Year Focus Document Fiscal Year Focus Autifony Therapeutics Autifony Therapeutics [Member] Autifony Therapeutics Operating lease assets Operating Lease, Right-of-Use Asset Employee compensation and benefits Accrued Employee Benefits, Current Total income tax benefit Effective Income Tax Rate Reconciliation, Percent Outside United States Outside United States Domestic and Foreign, Excluding United States [Member] Domestic and Foreign, Excluding United States Decreases related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Operating lease cost Operating Lease, Cost Plan Name [Domain] Plan Name [Domain] Unrecognized compensation cost, weighted-average period of recognition (in years) Weighted-average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition ESPP offering period (in months) Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Fixed offering period (months) with respect to the plan. Issuance of ordinary shares in conjunction with exercise of share options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Deferred tax assets, valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Equity [Abstract] Equity [Abstract] Goodwill, Acquired In-Process Research and Development, and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Summary Of Deferred Revenue [Table] Summary Of Deferred Revenue [Table] Summary Of Deferred Revenue [Table] Buildings Building [Member] Derivative Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Segment and Other Information Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Trademarks Trademarks [Member] Ireland Current Federal Tax Expense (Benefit) Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Leases Lessee, Leases [Policy Text Block] Intangible asset amortization Intangible asset amortization Amortization of Intangible Assets Teva Lawsuit Teva Lawsuit [Member] Teva Lawsuit Selling, general and administrative Selling, General and Administrative Expense Deferred tax assets, net Deferred tax assets Deferred Income Tax Assets, Net Debt Interest Rate Period [Domain] Debt Interest Rate Period [Domain] Debt Interest Rate Period [Domain] Total cash consideration paid to Chimerix Payments to Acquire Productive Assets Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Depreciation and amortization expense Depreciation, Depletion and Amortization Conversion rate of shares (in shares per dollar) Debt Instrument, Convertible, Conversion Ratio Accrued royalties Accrued Royalties, Current Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Dilutive effect of the 2026 Notes and the 2024 Notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Patent box incentive benefit Patent box incentive benefit, amount Effective Income Tax Rate Reconciliation, Patent Box Incentive Benefit, Amount Effective Income Tax Rate Reconciliation, Patent Box Incentive Benefit, Amount Borrowings under revolving credit facility Revolving Credit Facility [Member] Statutory tax rate difference Statutory income tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Award Group [Axis] Award Group [Axis] Award Group [Axis] Present value of lease liabilities Finance Lease, Liability Arrangement Duration Trading Arrangement Duration Computer equipment Computer Equipment [Member] Noncancelable purchase commitments due within one year Unrecorded Unconditional Purchase Obligation, Due in Next Rolling 12 Months Segments [Axis] Segments [Axis] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Europe Europe [Member] ESPP discount rate (as a percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Share-Based Compensation Share-Based Payment Arrangement [Text Block] Shares repurchased (in shares) Shares repurchased (in shares) Stock Repurchased and Retired During Period, Shares Chimerix Chimerix [Member] Chimerix Assets Assets: Assets [Abstract] Credit Facility [Axis] Credit Facility [Axis] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Patent box incentive benefit Effective Income Tax Rate Reconciliation, Patent Box Incentive Benefit, Percent Effective Income Tax Rate Reconciliation, Patent Box Incentive Benefit, Percent De-recognition of finance lease liability on lease assignment / termination De-Recognition Of Finance Lease Liability On Lease Assignment / Termination De-Recognition Of Finance Lease Liability On Lease Assignment / Termination Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Weighted-average grant-date fair value, RSUs and PRSUs forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Employee Benefit Plans Retirement Benefits [Text Block] Fair Value Measurement Fair Value Disclosures [Text Block] Business Combination [Line Items] Business Combination [Line Items] Credit Facility [Domain] Credit Facility [Domain] Shareholders’ equity: Equity, Attributable to Parent [Abstract] Derivative instrument liabilities Derivative Liability, Current Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Defitelio/defibrotide Defitelio/Defibrotide [Member] Defitelio/Defibrotide [Member] ESPP Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Interest rate (as a percentage) Debt Instrument, Interest Rate, Stated Percentage Operating lease liabilities, less current portion Operating lease liabilities Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Other Other Products [Member] Other Products [Member] Gross Amounts of Recognized Assets/ Liabilities Derivative Asset, Subject to Master Netting Arrangement, before Offset Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Loss recognized in AOCI to be reclassified over the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Ziihera Ziihera [Member] Ziihera Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Other Additions SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Totals Assets, Fair Value Disclosure Equity securities without readily determinable value, fair value Equity Securities without Readily Determinable Fair Value, Amount Number of operating business segments Number of Operating Segments Operating Leases Leases, Operating [Abstract] Repayment of 2024 Notes Repayments of convertible debt Repayments of Convertible Debt Deduction on subsidiary equity Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount Manufacturing equipment and machinery Machinery and Equipment [Member] Weighted-average grant-date fair value, RSUs and PRSUs granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Achievement target, percentage of awards granted Share-based Compensation Arrangement by Share-based Payment Award, Achievement Target, Percentage Of Awards Granted Share-based Compensation Arrangement by Share-based Payment Award, Achievement Target, Percentage Of Awards Granted United kingdom and united states Deferred Foreign Income Tax Expense (Benefit) Accounts Receivable Accounts Receivable [Member] Accumulated Other Comprehensive Income Loss [Table] Accumulated Other Comprehensive Income (Loss) [Table] Income Tax Benefit Income Tax Expense (Benefit), Continuing Operations [Abstract] Interest expense, net Interest Expense, Debt Total Neuroscience Total Neuroscience [Member] Total Neuroscience Change in tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Name Trading Arrangement, Individual Name Non-cash operating activities: Non-cash operating activities [Abstract] Non-cash operating activities [Abstract] Debt instrument, face amount Debt Instrument, Face Amount Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Infringed patents suit, number of patents Loss Contingency, Patents Allegedly Infringed, Number Name Awards Close in Time to MNPI Disclosures, Individual Name Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Current portion of lease liabilities Operating And Finance Lease, Liability, Current Operating And Finance Lease, Liability, Current Weighted-average grant-date fair value, outstanding, beginning balance (in dollars per share) Weighted-average grant-date fair value, outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Asset Acquisition [Line Items] Asset Acquisition [Line Items] Schedule of Percentage of Total Revenues from Customers Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Finance Lease Liability Maturities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] High-sodium oxybate AG royalty revenue High Sodium A G Oxybate Product Royalty Revenue [Member] High Sodium A G Oxybate Product Royalty Revenue Non-voting euro deferred shares, outstanding (in shares) Nonvoting Euro Deferred Shares, Shares Outstanding Nonvoting Euro Deferred Shares, Shares Outstanding Country Region Country Region Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Litigation Case [Axis] Litigation Case [Axis] Foreign Tax Authorities Foreign Tax Jurisdiction Foreign Tax Jurisdiction [Member] Auditor Firm ID Auditor Firm ID Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] United States, United Kingdom and Other Income (Loss) from Continuing Operations before Income Taxes, Foreign Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Outstanding Equity Awards Outstanding Equity Awards [Member] Outstanding Equity Awards Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Inventories Increase (Decrease) in Inventories Derivative assets Derivative Asset [Abstract] Cash Collateral Received (Pledged) Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Gross Amounts Offset in the Consolidated Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Asset Acquisition, Consideration Transferred, Equity Interest, Type [Axis] Asset Acquisition, Consideration Transferred, Equity Interest, Type [Axis] Asset Acquisition, Consideration Transferred, Equity Interest, Type Defined Contribution Plan [Table] Defined Contribution Plan [Table] All Executive Categories All Executive Categories [Member] Schedule of Net Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 61,435 and 60,631 shares issued and outstanding at December 31, 2025 and 2024, respectively Common Stock, Value, Issued Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Intangible assets Deferred Tax Assets, Intangible Assets Deferred Tax Assets, Intangible Assets Modeyso Modeyso [Member] Modeyso Commitments and contingencies (Note 13) Commitments and Contingencies Business Combination [Axis] Business Combination [Axis] Deferred, change in tax rates Deferred Income Tax Expense (Benefit), Change In Tax Rate [Abstract] Deferred Income Tax Expense (Benefit), Change In Tax Rate [Abstract] Lumryz Product For Narcolepsy Indications Lumryz Product For Narcolepsy Indications [Member] Lumryz Product For Narcolepsy Indications Accrued construction-in-progress Accrued Construction-In-Progress, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction-in-progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Concentration Risk [Line Items] Concentration Risk [Line Items] Net deferred tax assets (liabilities) Deferred Tax Assets, Net PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Weighted-average remaining lease term (years) Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Schedule II Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Hedging Designation [Axis] Hedging Designation [Axis] Scenario [Axis] Scenario [Axis] Schedule of Reconciliation of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of Asset Acquisition Asset Acquisition [Table Text Block] Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Domestic Plan Domestic Plan [Member] Derivative Contract [Domain] Derivative Contract [Domain] Requisite service periods (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Numerator: Numerator [Abstract] Numerator [Abstract] Name Forgone Recovery, Individual Name Grants expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Pharmaceuticals Products Segment Pharmaceuticals Products Segment [Member] Pharmaceuticals Products Segment Infringed patents suit, number of patents Infringed Patents Suit, Number Of Patents Infringed Patents Suit, Number Of Patents Amended and Restated 2007 Non-Employee Directors Stock Award Plan Two Thousand Seven Non Employee Directors Stock Option Plan [Member] Two Thousand Seven Non-Employee Directors Stock Option Plan [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Allowance for sales discounts Allowance For Sales Discounts [Member] Allowance For Sales Discounts [Member] Award Group [Domain] Award Group [Domain] Award Group [Domain] Acquired in-process research and development Payments to Acquire In Process Research and Development Other Than Through Business Combination Payments to Acquire In Process Research and Development Other Than Through Business Combination Proceeds from employee equity incentive and purchase plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised 2030 Notes Exchangeable Senior Notes Due 2030 [Member] Exchangeable Senior Notes Due 2030 Avadel Avadel [Member] Avadel Foreign exchange Goodwill, Foreign Currency Translation, Gain (Loss) Total lease assets Operating Lease And Finance Lease Right-Of Use Asset Operating Lease And Finance Lease Right-Of Use Asset Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Finite-Lived Intangible Assets by Major Class [Table] Intangible Asset, Finite-Lived [Table] In-process research and development Indefinite-Lived Intangible Assets Acquired Geographical [Axis] Geographical [Axis] GW Incentive Plans GW Incentive Plans [Member] GW Incentive Plans Derivative liabilities Derivative Liability [Abstract] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Change in estimates Change in estimate, amount Effective Income Tax Rate Reconciliation, Change In Estimate, Amount Effective Income Tax Rate Reconciliation, Change In Estimate, Amount Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Foreign exchange gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Forecast Forecast [Member] Tris Pharma Patent Litigation Tris Pharma Patent Litigation [Member] Tris Pharma Patent Litigation Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Aggregate intrinsic value, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value 2021 Credit Agreement, Dollar Term Loan Two Thousand Twenty One Credit Agreement, Dollar Term Loan [Member] Two Thousand Twenty One Credit Agreement, Dollar Term Loan Scheduled Long-Term Debt Maturities Long-Term Debt, Fiscal Year Maturity [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five Ownership percentage (as a percentage) Subsidiary, Ownership Percentage, Parent Non-deductible financing costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Financing Costs, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Financing Costs, Percent Foreign Derived Intangible Income benefit Effective Income Tax Rate Reconciliation, FDII, Percent Tranche B-1 Dollar Term Loan Tranche B 1 Dollar Term Loan [Member] Tranche B 1 Dollar Term Loan Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income (Loss) per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Tax credit carryforwards Tax Credit Carryforward, Amount GW Pharmaceuticals plc GW Pharmaceuticals plc [Member] GW Pharmaceuticals plc Thereafter Finance Lease, Liability, to be Paid, after Year Five Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2029 Secured Notes Secured Notes 2029 Secured Notes [Member] 2029 Secured Notes Award Timing Disclosures [Line Items] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Shareholders' Equity Equity [Text Block] Debt Interest Rate Period One Debt Interest Rate Period One [Member] Debt Interest Rate Period One Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Construction-in-progress Construction in Progress [Member] Other Other Accrued Liabilities, Current Schedule of Reconciliation of Income Taxes at the Statutory Income Tax Rate to Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vyxeos Vyxeos [Member] Vyxeos [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Share repurchases Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Cash Equivalents and Investments Cash And Cash Equivalents And Investments, Policy [Policy Text Block] Cash And Cash Equivalents And Investments, Policy Customer [Axis] Customer [Axis] Income (loss) from operations Operating Income (Loss) Line of Credit Line of Credit [Member] Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Other Deferred Other Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Deferred Other Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate Employee equity incentive and purchase plans Equity Unit Purchase Agreements [Member] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Net Unrealized Gain (Loss) From Hedging Activities Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other Deferred Tax Liabilities, Other Payables and Accruals [Abstract] Payables and Accruals [Abstract] Statement [Table] Statement [Table] Deferred tax benefit Total deferred tax benefit Deferred Income Tax Expense (Benefit) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Lapse of the applicable statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Other Other foreign jurisdictions Foreign Tax Jurisdiction, Other [Member] De-recognition of finance lease asset on lease assignment / termination De-Recognition Of Finance Lease Asset On Lease Assignment / Termination De-Recognition Of Finance Lease Asset On Lease Assignment / Termination Non-deductible acquired in-process research and development expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Variable Rate [Domain] Variable Rate [Domain] Defitelio Patent Litigation Defitelio Patent Litigation [Member] Defitelio Patent Litigation Finance lease liabilities Finance Lease, Liability, Noncurrent Increase in shares authorized for issuance under deferred compensation plan (in shares) Deferred Compensation Arrangement With Individual, Increase In Shares Authorized For Issuance Deferred Compensation Arrangement With Individual, Increase In Shares Authorized For Issuance All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Income tax benefit from share-based compensation expense Share-Based Payment Arrangement, Expense, Tax Benefit Shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Termination Date Trading Arrangement Termination Date Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] November 2016 Share Repurchase Program November 2016 Share Repurchase Program [Member] November 2016 Share Repurchase Program [Member] Raw materials Inventory, Raw Materials, Net of Reserves Operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Information and Activity Related to Share Option Plans Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-average ordinary shares used in per share calculations - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Land and buildings Land and Building [Member] Schedule of Basic and Diluted Net Income (Loss) per Ordinary Share Computation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Asset derivatives Derivative Asset, Gross Asset Including Not Subject to Master Netting Arrangement Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Debt covenant, unrestricted cash requirement, percentage of principal outstanding Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Required, Percentage Of Principal Outstanding Debt Instrument, Covenant, Unrestricted Cash Required, Percentage Of Principal Outstanding Debt Disclosure [Abstract] Debt Disclosure [Abstract] Saniona Saniona [Member] Saniona Royalties and contract revenues Product And Services, Royalties And Contract Revenue [Member] Product And Services, Royalties And Contract Revenue [Member] Scenario [Domain] Scenario [Domain] Debt Interest Rate Period [Axis] Debt Interest Rate Period [Axis] Debt Interest Rate Period 2007 Employee Stock Purchase Plan Two Thousand Seven Employee Stock Purchase Plan [Member] Two Thousand Seven Employee Stock Purchase Plan [Member] Estimated litigation liability, current Estimated Litigation Liability, Current Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Ordinary shares, nominal value (in dollars per share) Common Stock, Par or Stated Value Per Share Jazz Securities Designated Activity Company Jazz Securities Designated Activity Company [Member] Jazz Securities Designated Activity Company 2007 Directors Award Plan Two Thousand Seven Directors Award Plan [Member] Two Thousand Seven Directors Stock Award Plan McKesson McKesson Corporation [Member] McKesson Corporation [Member] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Effects of cross-border tax laws Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] Deferred tax asset valuation allowance SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Operating cash outflows from finance leases Finance Lease, Interest Payment on Liability Settlement amount Litigation Settlement, Amount Awarded to Other Party Maximum allowable dividend and restricted percentage Debt Instrument, Covenant, Maximum Allowable Dividend And Restricted Percentage Debt Instrument, Covenant, Maximum Allowable Dividend And Restricted Percentage Consideration Asset Acquisition, Consideration Transferred [Abstract] Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Subsequent Events Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Nominal Strike Price Options Nominal Strike Price Options [Member] Nominal Strike Price Options Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Line of credit facility, commitment fee percentage (as a percentage) Line of Credit Facility, Commitment Fee Percentage 2030 Finance Lease, Liability, to be Paid, Year Five Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Debt repurchased amount Debt Instrument, Repurchased Face Amount Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Domestic tax effects Domestic Tax Effects [Abstract] Domestic Tax Effects Offsetting Assets [Line Items] Offsetting Assets [Line Items] Derivative Financial Instruments Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Other royalty and contract revenues Other Royalties And Contract Revenue [Member] Other Royalties And Contract Revenue Variable Rate [Axis] Variable Rate [Axis] Unamortized - debt issuance costs Unamortized Debt Issuance Expense Acquisition-related increases Unrecognized Tax Benefits, Increase Resulting from Acquisition Quarterly amortization rate, percentage (as a percentage) Debt Instrument, Quarterly Amortization Rate, Percentage Debt Instrument, Quarterly Amortization Rate, Percentage Counterparty Name [Axis] Counterparty Name [Axis] Number of trading days Debt Instrument, Convertible, Threshold Trading Days Estimated Fair Value Available-for-sale securities Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member]